Last reviewed · How we verify
Semaglutide, Empagliflozin
This combination uses a GLP-1 receptor agonist to reduce appetite and blood sugar while an SGLT2 inhibitor increases urinary glucose excretion to lower blood glucose.
This combination uses a GLP-1 receptor agonist to reduce appetite and blood sugar while an SGLT2 inhibitor increases urinary glucose excretion to lower blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Semaglutide, Empagliflozin |
|---|---|
| Also known as | Semaglutide (GLP-1RA), Empagliflozin (SGLT-2i) |
| Sponsor | University Medical Center, Kazakhstan |
| Drug class | GLP-1 receptor agonist + SGLT2 inhibitor combination |
| Target | GLP-1 receptor; SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Semaglutide activates GLP-1 receptors to enhance insulin secretion, slow gastric emptying, and promote satiety, thereby reducing blood glucose and body weight. Empagliflozin inhibits sodium-glucose cotransporter 2 in the kidney, preventing glucose reabsorption and promoting urinary glucose excretion. Together, these mechanisms provide complementary glycemic control and cardiovascular/renal benefits.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Genital mycotic infections
- Urinary tract infection
- Hypoglycemia
Key clinical trials
- Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes (PHASE2)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (PHASE1, PHASE2)
- Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (PHASE4)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide, Empagliflozin CI brief — competitive landscape report
- Semaglutide, Empagliflozin updates RSS · CI watch RSS
- University Medical Center, Kazakhstan portfolio CI